{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:15:55Z","timestamp":1789542955734,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp;amp; Syst Pharma"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra\u2010rare, life\u2010threatening thrombotic microangiopathy caused by a severe inherited deficiency of ADAMTS13, a von Willebrand factor (VWF) cleaving enzyme. Inadequate clinical endpoint data often make it challenging to statistically power clinical trials in ultra\u2010rare diseases. Therefore, utilizing in\u00a0vitro, <jats:italic>adamts13<\/jats:italic>\u2010knockout mouse, literature\u2010based, and clinical data, a quantitative systems pharmacology (QSP) model was developed to describe the mechanistic relationship between ADAMTS13, VWF, and platelet count, and to supplement evidence from clinical trials of recombinant ADAMTS13 (rADAMTS13) for the treatment of cTTP. The effect of long\u2010term prophylaxis with rADAMTS13 versus plasma\u2010based therapies (PBT) on platelet count in patients with cTTP was investigated. One\u2010year clinical trial simulations of thrombocytopenia occurrences in 1000 virtual patients, phenotype\u2010matched to a cTTP Phase 3 study population (NCT03393975), were produced. Simulations suggested that once\u2010weekly (Q1W) or once every 2\u2009weeks (Q2W) rADAMTS13 administered over 1\u2009year resulted in fewer patients experiencing thrombocytopenia versus patients treated with PBT (e.g., Q2W [rADAMTS13] relative to Q2W [PBT], HR\u2009=\u20090.47 [platelet count drop to &lt;\u2009150 \u00d7\u200910<jats:sup>9<\/jats:sup>\/L], HR\u2009=\u20090.41 [&lt;\u2009100 \u00d7\u200910<jats:sup>9<\/jats:sup>\/L]). These results provide confirmative evidence to support the use of rADAMTS13 in cTTP by integrating the current mechanistic understanding of interactions between ADAMTS13 and VWF multimers as its substrate, as well as key downstream parameters, primarily platelet count. Virtual patient clinical simulations from the QSP model supported the regulatory approval of rADAMTS13 in cTTP, highlighting the significant potential of QSP modeling to supplement clinical trial data in rare disease drug development.<\/jats:p>","DOI":"10.1002\/psp4.70063","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T12:40:44Z","timestamp":1751632844000},"page":"1575-1586","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quantitative Systems Pharmacology Modeling of Platelet Responses to Recombinant <scp>ADAMTS13<\/scp> in Patients With Congenital Thrombotic Thrombocytopenic Purpura"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-8821","authenticated-orcid":false,"given":"Cameron","family":"McBride","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaolong","family":"Jiang","sequence":"additional","affiliation":[{"name":"RES Group Inc.  Needham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"RES Group Inc.  Needham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tolsma","sequence":"additional","affiliation":[{"name":"RES Group Inc.  Needham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Patwari","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Mellg\u00e5rd","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Vakilynejad","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-6844","authenticated-orcid":false,"given":"Indranil","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy Z. X.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.216796"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000065"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608422104"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-884700"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.20"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030536"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23527"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06264.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15010"},{"key":"e_1_2_10_11_1","unstructured":"US Food and Drug Administration ADZYNMA Lyophilized Powder for Injection for Intravenous Use. Prescribing Information https:\/\/www.fda.gov\/media\/173756\/download?attachment."},{"key":"e_1_2_10_12_1","unstructured":"ADZYNMAandEuropean Medicines Agency Summary of Product Characteristics https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adzynma."},{"key":"e_1_2_10_13_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) Japan Adzynma Intravenous 1500 https:\/\/www.pmda.go.jp\/files\/000272019.pdf."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12567"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13208"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200221999210101233340"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1693"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314793"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.07.009"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016112803520738"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1743-8"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.140"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12548"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788026"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/918916"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13728"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1153"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02808.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2002.tb00099.x"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968132.86513.06"},{"key":"e_1_2_10_32_1","volume-title":"Application of a QSP Model for Recombinant Human ADAMTS13 in Sickle Cell Disease","author":"Nguyen H.","year":"2020"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13341"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1515\/9781400883066"},{"key":"e_1_2_10_35_1","unstructured":"ClinicalTrials.gov Study of rADAMTS\u201013 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (SOAR\u2010HI) Clinical Trial Protocol https:\/\/cdn.clinicaltrials.gov\/large\u2010docs\/08\/NCT03922308\/Prot_004.pdf."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010189314"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1137\/1.9781611971224.ch1"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-9274(97)00050-0"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-1098(88)90003-9"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1145\/279232.279236"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1713735"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000542"},{"key":"e_1_2_10_43_1","unstructured":"Food and Drug Administration Summary basis for regulatory action \u2013 ADZYNMA https:\/\/www.fda.gov\/media\/174318\/download."}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:02:37Z","timestamp":1760500957000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.70063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/psp4.70063"],"URL":"https:\/\/doi.org\/10.1002\/psp4.70063","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"2024-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}